B[AI pharmaceutical concept was active at the beginning of the trading session, Hongbo Pharmaceutical reached its daily limit of 20cm] On October 16, the AI pharmaceutical concept was active at the beginning of the trading session. Hongbo Pharmaceuticals hit the 20cm daily limit, with Jiankai Technology, Boji Pharmaceuticals, Bepsis, Chengdu Pioneer, Yaoshi Technology, and Northcoin leading the gains. According to news, on October 15, AstraZeneca and Insitro signed an artificial intelligence drug research and development agreement worth US$1.86 billion, aiming to help find new drugs to treat liver and heart diseases. B[AI pharmaceuticals and CRO concepts pick up in the afternoon, Berry Genetics 6 days and 3 boards] On October 9th, AI pharmaceuticals and CRO concepts picked up in the afternoon, Berry Genes went straight up to the daily limit, out of 6 days and 3 boards, Technomax rose by more than 10%, Jinshi Yaoyao, Tuojing Life, InnoCare, Shenzhou Cells, etc. quickly surged higher. According to the news, Isomorphic Labs, an AI drug research and development start-up, is advancing preliminary negotiations for a new round of financing. The post-investment valuation of this round is at least US$40 billion, and is expected to reach a maximum of US$50 billion. B[The concept of AI pharmaceuticals has moved up and Berry Gene has risen by the daily limit] On September 24th, the concept of AI pharmaceuticals has moved upwards in early trading, and Berry Gene has risen by the daily limit. BGI, Rongtai Health, Saili Medical, Yiqiao Shenzhou, and Jinyu Medical followed suit. On the news, Anthropic announced the establishment of a life science research team and laboratory, and announced the early results of Claude's participation in biological research. Researchers said that after analyzing more than 200,000 reverse transcriptase (RT) sequences, Claude discovered a previously undescribed enzyme system and named it "array-associated reverse transcriptase" (ART). B[AI pharmaceuticals and CRO concepts have repeatedly strengthened, and Novogene has reached a daily limit of 20cm] On September 21, AI pharmaceuticals and CRO concepts have repeatedly strengthened, and Novogene has reached a daily limit of 20cm. Hongbo Pharmaceuticals, Chengdu HitGen, Boji Pharmaceuticals, Berry Genetics, and Seli Medical followed suit. On the news, on September 18, ten departments including the Ministry of Industry and Information Technology jointly issued the "15th Five-Year Plan for the Development of the Pharmaceutical Industry." The plan proposes to accelerate the research and development of drugs enabled by new technologies such as artificial intelligence, quantum computing, supercomputing, and computational medicine, and explore new models of pharmaceutical and device production such as ultra-limited manufacturing, space pharmaceuticals, and biomanufacturing. B[AI pharmaceutical concept rebounded with shock and Chengdu Pioneer rose by more than 10%] On September 16th, the AI pharmaceutical concept rebounded with shock and rebound in the afternoon, with Chengdu Pioneer rising by more than 10%. Nearshore Protein, Kailer Shares, Medicilon, Hongbo Pharmaceutical, Boji Pharmaceutical, and Yaoshi Technology were among the top gainers. In terms of news, on September 14, the State Council Information Office held a press conference to introduce the decisive progress in promoting the construction of a healthy China. The National Health Commission proposed that attention should be paid to technological empowerment, especially the widespread application of artificial intelligence technology and biotechnology in the health field.
— All loaded —
